Xarelto: new oral anticoagulantBayer's Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheim's Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July. Insect repellents: new patient guidelines Liberals promise catastrophic drug plan New Listeria guidelines New Natural Health Products database now available New guidelines: bacterial vaginosis in pregnancy Study finds impact of drug advertising exaggerated Valcyte: new dosage form Awards predict top sellers Seroquel/Seroquel XR: expanded indication First Previous 2185 2186 2187 2188 2189 Next Last
